scholarly journals The role of age in treatment‐related adverse events in patients with head and neck cancer: A systematic review

Head & Neck ◽  
2019 ◽  
Vol 41 (7) ◽  
pp. 2410-2429 ◽  
Author(s):  
Andrés Coca‐Pelaz ◽  
Gyorgy B. Halmos ◽  
Primož Strojan ◽  
Remco Bree ◽  
Paolo Bossi ◽  
...  
Keyword(s):  
Systematic Review ◽  
Head And Neck Cancer ◽  
Adverse Events ◽  
Head And Neck ◽  
Neck Cancer

scholarly journals Circulating MicroRNAs as Prognostic Molecular Biomarkers in Human Head and Neck Cancer: A Systematic Review and Meta-Analysis

2019 ◽  
Vol 2019 ◽  
pp. 1-12 ◽  
Author(s):  
Shree Ram Lamichhane ◽  
Thanuja Thachil ◽  
Harriet Gee ◽  
Natalie Milic
Keyword(s):  
Systematic Review ◽  
Overall Survival ◽  
Head And Neck Cancer ◽  
Head And Neck ◽  
Cancer Patients ◽  
Neck Cancer ◽  
Meta Analysis ◽  
Prognostic Role ◽  
Circulating Micrornas

Background. Circulating microRNAs (miRNAs) are potential molecular biomarkers for cancer detection; however, little is known about their prognostic role in head and neck cancer. This current study is aimed at evaluating the role of novel miRNAs in the survival of head and neck cancer patients. Materials and Methods. We performed a systematic literature search using online databases for articles published between December 2006 and February 2019. A meta-analysis was conducted to assess the correlation between miRNA expressions and overall survival (OS) among the selected head and neck cancer studies. After multilevel screening by reviewers, meta-analysis was performed using hazard ratios (HR) and associated 95% confidence interval (CI) of survival to calculate a pooled effect size. Result. A total of 1577 patients across 13 studies were included in the literature review, with 18 miRNAs upregulated and 4 miRNAs downregulated predicting a poor overall survival. The forest plot generated using cumulated survival data resulted in a pooled HR value of 2.943 (95% CI: 2.394-3.618) indicating a strong association of dysregulated miRNA expression with a poor outcome. Only 2 miRNAs—low levels of miR-9 and high levels of miR-483-5p—were observed in two studies, both showing a significant association with overall cancer survival. Conclusion. To our knowledge, this is the first comprehensive systematic review and meta-analysis that examines the prognostic role of circulating miRNAs from blood in head and neck cancer patients. The combined effect estimates a HR across multiple studies and also supports the previous individual findings that an alteration in miRNA expression is highly associated with poor prognosis. This has the potential to use serum and/or plasma miRNAs as biomarkers and become novel tools for predicting the prognosis of head and neck cancer patients in the near future.

Role of Steroids in Preventing Osteoradionecrosis of the Head and Neck: A Systematic Review

2019 ◽  
Vol 128 (5) ◽  
pp. 441-446 ◽  
Author(s):  
Blake S. Raggio ◽  
Ryan D. Winters
Keyword(s):  
Systematic Review ◽  
Radiation Therapy ◽  
Head And Neck Cancer ◽  
Confidence Interval ◽  
Head And Neck ◽  
Neck Cancer ◽  
Age Groups ◽  
Data Sources ◽  
Statistical Heterogeneity

Objective: The aim of this study was to summarize the effectiveness of steroids in the prevention of osteoradionecrosis of the head and neck. Data Sources: PubMED, MEDLINE, Embase, Google Scholar, and Cochrane trial registries. Methods: A systematic review of these data sources was performed through September 2018 using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Included were English-language studies evaluating patients of all age groups diagnosed with head and neck cancer who underwent radiation therapy while receiving peritreatment steroids compared with those who did not receive steroids. Results: Two retrospective cohort studies were identified for qualitative review. On the basis of analysis of 25 328 participants (36-82 years of age) with head and neck cancer who underwent radiation therapy, the use of peritreatment steroids was associated with a significantly lower risk for osteoradionecrosis in both studies, with a hazard ratio of 0.74 (95% confidence interval, 0.59-0.94; P = .012) and a relative risk of 0.04 (95% confidence interval, 0.003-0.560; P = .017). Meta-analysis was precluded by clinical and statistical heterogeneity. Overall, the studies were of limited quality with high risk for bias and poor methodology. Conclusions: Limited retrospective data suggest that steroids are predictive of a reduced risk for osteoradionecrosis; however, no definitive conclusions can be made given the poor quality of the available literature. Well-designed, comparison-controlled trials are needed to clarify the promising role of steroids in the prevention of osteoradionecrosis of the head and neck.

The role of allied healthcare professionals in head and neck cancer surveillance: A systematic review

2019 ◽  
Vol 45 (1) ◽  
pp. 83-98 ◽  
Author(s):  
John Rocke ◽  
Oliver Mclaren ◽  
John Hardman ◽  
George Garas ◽  
Matthew E Smith ◽  
...  
Keyword(s):  
Systematic Review ◽  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Healthcare Professionals ◽  
Cancer Surveillance ◽  
Allied Healthcare

Role of macrophage migration inhibitory factor in head and neck cancer and novel therapeutic targets: A systematic review

Head & Neck ◽  
2017 ◽  
Vol 39 (12) ◽  
pp. 2573-2584 ◽  
Author(s):  
Jérôme R. Lechien ◽  
Amir Nassri ◽  
Nadege Kindt ◽  
David N. Brown ◽  
Fabrice Journe ◽  
...  
Keyword(s):  
Systematic Review ◽  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Migration Inhibitory Factor ◽  
Macrophage Migration Inhibitory Factor ◽  
Inhibitory Factor ◽  
Macrophage Migration ◽  
Novel Therapeutic

Serious immune‐related adverse events in patients with head and neck cancer after checkpoint blockade: Systematic review

Head & Neck ◽  
2019 ◽  
Vol 41 (11) ◽  
pp. 4036-4050 ◽  
Author(s):  
Mohsin Shah ◽  
Mona K. Jomaa ◽  
Renata Ferrarotto ◽  
Sai‐Ching J. Yeung ◽  
Ehab Y. Hanna ◽  
...  
Keyword(s):  
Systematic Review ◽  
Head And Neck Cancer ◽  
Adverse Events ◽  
Head And Neck ◽  
Neck Cancer ◽  
Checkpoint Blockade

The controversial role of electrochemotherapy in head and neck cancer: a systematic review of the literature

2017 ◽  
Vol 274 (6) ◽  
pp. 2389-2394 ◽  
Author(s):  
Riccardo Lenzi ◽  
Luca Muscatello ◽  
Alberto Maria Saibene ◽  
Giovanni Felisati ◽  
Carlotta Pipolo
Keyword(s):  
Systematic Review ◽  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Review Of The Literature

scholarly journals Programmed Cell Death 1 Receptor / Programmed Death-Ligand1 (PD‐1/PD‐L1 ) Inhibitors Alone or with Conventional Therapy versus Standard of Care for Head and Neck Cancer: A Systematic Review and Meta-Analysis

2021 ◽  
Author(s):  
Xin Huang ◽  
Jie Zhang ◽  
Hongying Ruan
Keyword(s):  
Systematic Review ◽  
Head And Neck Cancer ◽  
Adverse Events ◽  
Head And Neck ◽  
Outcome Measures ◽  
Neck Cancer ◽  
Conventional Therapy ◽  
Standard Of Care ◽  
Cochrane Library ◽  
Control Groups

Objectives As a pivotal part of precision therapy, PD‐1/PD‐L1 immunotherapy has been gradually used in head and neck cancer (HNC). We investigated the effect and adverse events of PD‐1/PD‐L1 inhibitors alone or with conventional therapy. Design The groups using PD-1/PD-L1 immunotherapy or combining with conventional therapy were defined as the experimental groups, while the standard of care were the control groups. Cochrane Library, Embase, PubMed, and Web of Science were undertaken to identify literature up to November 20, 2020. Overall survival (OS) and progression-free survival (PFS) were the primary outcome measures. Secondary outcome measures included objective response rate (ORR), disease control rate (DCR), any grade and grade≥3 adverse events (AE). Results Five randomized controlled trials (RCTs) and nine single-arm trials were included in the systematic review. The OS of the experimental groups was better than the control groups (OR = 0.63, 95%CI: 0.49‐0.82, I²=35%, P=0.0004), particularly in patients who smoke current/former or with human papillomavirus negative (HPV-). The experimental groups had longer OS than the control groups in patients with PD-L1 positive (OR = 0.75, 95% CI: 0.65‐0.85, I²=0%, P<0.0001). Patients with HPV positive (HPV+) had more favorable OS than those with HPV- (OR = 0.56, 95%CI:0.44-0.71, I²=39%, P<0.00001). There were statistical differences in AEs (e.g., fatigue, rash, hypothyroidism, etc.) and no statistical differences in PFS, ORR, and DCR. Conclusion PD-1/PD-L1 immunotherapy or combining with conventional therapy can improve the treatment effect and induce fewer adverse events of digestion and blood system, except for hypothyroidism.

Sign in / Sign up

Export Citation Format

Share Document